Last updated: February 15, 2026
Overview of the Drug
NDC 51407-0524 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb. Approved for multiple indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and other cancers, nivolumab commands a significant share in the immuno-oncology market. Its approval date varies by indication, with initial approval for melanoma in December 2014.
Market Context
The global immuno-oncology market has grown rapidly, driven by approvals of PD-1/PD-L1 inhibitors. Nivolumab's key competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and cemiplimab (Libtayo).
– The product generated approximately $7.8 billion in worldwide sales in 2022.
– The U.S. market accounted for roughly 60% of total sales, reflecting high adoption due to reimbursement and regulatory support.
– Growth projections suggest a compound annual growth rate (CAGR) of 10-12% through 2028, supported by new indications and combinations.
Pricing Overview
In the U.S., the average wholesale price (AWP) per 40 mg vial is approximately $4,548; for 240 mg, around $27,290. The dosing regimen typically involves 240 mg every two weeks. Typical treatment courses range from 6 months to one year, translating into an approximate treatment cost of $70,000 to $150,000 per patient annually.
Key factors influencing pricing:
- Market Exclusivity: Patent protections extend primarily until 2030, with some patents potentially lasting to 2034 due to extensions.
- Reimbursement Policies: Medicare, Medicaid, and private insurers negotiate formulary access, impacting net prices.
- Pricing Trends: Prices have somewhat stabilized, but competitive pressures from biosimilars or new entrants could induce reductions.
Price Projections
Assuming sales growth continues at a CAGR of approximately 10% through 2028, with existing patents intact, the following projections are made:
| Year |
Estimated Worldwide Sales |
Average Price per Treatment Year |
Key Assumptions |
| 2023 |
$8.6 billion |
$70,000 |
Steady growth, no significant price erosion, stable indications |
| 2024 |
$9.4 billion |
$68,000 |
Slight price reduction due to competitive pressures, expansion of indications |
| 2025 |
$10.3 billion |
$66,000 |
Broad use in combination therapies, potential biosimilar entry in 2026 |
| 2026 |
$11.4 billion |
$64,000 |
Biosimilar competition begins reducing net prices, patent cliff approaches |
| 2027 |
$12.4 billion |
$62,000 |
Biosimilar market entry, price adjustments, increased adoption |
| 2028 |
$13.5 billion |
$60,000 |
Market acceptance of biosimilars, negotiated discounts |
Competitive Dynamics
- Biosimilars are expected to enter the market post-patent expiration, potentially reducing prices by 20-30% initially.
- Combination therapies with other immunomodulators could affect pricing protocols.
- Market expansion into new indications (e.g., gastric or urothelial cancers) enhances revenue streams but may pressure pricing strategies.
Economic and Reimbursement Influences
- Payer resistance to high-cost therapies influences net price realization.
- Value-based agreements link reimbursement to clinical outcomes, potentially leading to price adjustments.
Key Factors Affecting Price Trajectory
- Patent expirations and biosimilar development timelines.
- Regulatory and reimbursement policies.
- Clinical trial outcomes expanding or restricting indications.
- Competitive launches of novel checkpoint inhibitors or combination regimens.
Summary of Market & Price Outlook
Nivolumab (NDC 51407-0524) remains a high-value immunotherapy driven by its broad indication portfolio and market penetration. Price stability is expected until biosimilar competition significantly influences the landscape, likely starting around 2026. The total market will grow driven by new indication approvals, but price erosion will accompany increased competition.
Key Takeaways
- Nivolumab recorded ~$7.8 billion worldwide sales in 2022.
- U.S. treatment costs average around $70,000 annually per patient, with prices stabilizing through 2025.
- Patents extend until at least 2030, delaying biosimilar entry, which could reduce prices by 20-30%.
- Market growth is projected at 10-12% CAGR through 2028, driven by indication expansion and increasing adoption.
- Biosimilar competition and value-based reimbursement strategies are primary forces shaping future prices.
FAQs
1. When are biosimilars for nivolumab expected to enter the market?
Biosimilars are anticipated to launch around 2026-2027, depending on patent litigation and regulatory approvals.
2. How might patent expirations impact nivolumab's market share?
Patent expirations could lead to a decline in net prices and increased market share for biosimilars, potentially reducing revenue by 20-30% initially.
3. Are there any new indications that could affect nivolumab’s pricing?
Yes, approval of new indications, such as gastric or head and neck cancers, could expand market size but may also lead to pricing negotiations.
4. How do reimbursement policies influence nivolumab pricing?
Reimbursement negotiations and formulary placements determine net prices. Value-based arrangements may limit reimbursement for less effective use cases.
5. What is the outlook for nivolumab’s market share compared to competitors?
It remains a leading PD-1 inhibitor owing to broad approvals. Competition from pembrolizumab and new agents may shift market dynamics but nivolumab’s established position supports continued prominence.
Citations
[1] IQVIA, "The Impact of Biosimilar Entry on Oncology Drug Prices," 2023.
[2] Bristol-Myers Squibb, "Opdivo (Nivolumab) Prescribing Information," 2022.
[3] EvaluatePharma, "Immuno-oncology Market Outlook 2023-2028," 2023.
